Ieq Capital LLC Makes New Investment in Sarepta Therapeutics, Inc. $SRPT

Ieq Capital LLC acquired a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 131,822 shares of the biotechnology company’s stock, valued at approximately $2,369,000. Ieq Capital LLC owned approximately 0.12% of Sarepta Therapeutics as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Kestra Advisory Services LLC purchased a new position in Sarepta Therapeutics in the fourth quarter valued at approximately $25,000. iSAM Funds UK Ltd purchased a new stake in shares of Sarepta Therapeutics during the 3rd quarter worth approximately $25,000. Meeder Asset Management Inc. acquired a new position in shares of Sarepta Therapeutics in the 2nd quarter valued at $27,000. Ancora Advisors LLC boosted its holdings in shares of Sarepta Therapeutics by 200.0% in the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 1,000 shares in the last quarter. Finally, Allworth Financial LP grew its position in shares of Sarepta Therapeutics by 2,098.8% in the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 1,721 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on SRPT. Piper Sandler cut their price target on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a research note on Thursday, July 9th. Wall Street Zen lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Wolfe Research raised Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 target price for the company in a report on Thursday, July 9th. Weiss Ratings cut Sarepta Therapeutics from a “sell (d)” rating to a “sell (e+)” rating in a research report on Wednesday, August 19th. Finally, HC Wainwright restated a “buy” rating on shares of Sarepta Therapeutics in a research note on Tuesday, July 28th. Nine equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and five have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $25.06.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT opened at $18.92 on Wednesday. The company has a 50-day simple moving average of $17.53 and a 200-day simple moving average of $18.26. Sarepta Therapeutics, Inc. has a one year low of $14.68 and a one year high of $25.32. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.62 and a current ratio of 4.42. The stock has a market capitalization of $2.00 billion, a price-to-earnings ratio of -6.52, a PEG ratio of 0.27 and a beta of 0.23.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.42. The firm had revenue of $401.25 million for the quarter, compared to analyst estimates of $366.39 million. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%.The business’s revenue was down 34.3% on a year-over-year basis. During the same quarter last year, the company posted $2.02 earnings per share. On average, analysts predict that Sarepta Therapeutics, Inc. will post 3.43 EPS for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.